Abivax publishes financial reports with the French and U.S. securities regulatory agencies
Abivax (ABVX) has announced the filing of its Universal Registration Document with the French Financial Market Authorities (AMF) and its Annual Report (20-F) with the U.S. Securities and Exchange Commission (SEC) on March 24, 2025.
The Universal Registration Document contains the 2024 annual financial report, management report including corporate governance report, and statutory auditors' reports. These documents will be accessible on Abivax's website, AMF, and SEC's EDGAR system.
Abivax is a clinical-stage biotech company developing treatments for chronic inflammatory diseases. Their lead drug candidate, obefazimod (ABX464), is currently in Phase 3 clinical trials for treating moderately to severely active ulcerative colitis.
Abivax (ABVX) ha annunciato il deposito del suo Documento di Registrazione Universale presso le Autorità di Mercato Finanziario Francesi (AMF) e del suo Rapporto Annuale (20-F) presso la Commissione per i Titoli e gli Scambi degli Stati Uniti (SEC) il 24 marzo 2025.
Il Documento di Registrazione Universale contiene il rapporto finanziario annuale 2024, il rapporto di gestione che include il rapporto sulla governance aziendale e i rapporti dei revisori legali. Questi documenti saranno accessibili sul sito web di Abivax, presso l'AMF e nel sistema EDGAR della SEC.
Abivax è un'azienda biotech in fase clinica che sviluppa trattamenti per malattie infiammatorie croniche. Il loro principale candidato farmaco, obefazimod (ABX464), è attualmente in prove cliniche di Fase 3 per il trattamento della colite ulcerosa moderatamente attiva a grave.
Abivax (ABVX) ha anunciado la presentación de su Documento de Registro Universal ante las Autoridades del Mercado Financiero de Francia (AMF) y su Informe Anual (20-F) ante la Comisión de Valores de EE. UU. (SEC) el 24 de marzo de 2025.
El Documento de Registro Universal incluye el informe financiero anual 2024, el informe de gestión que abarca el informe de gobernanza corporativa y los informes de los auditores legales. Estos documentos estarán disponibles en el sito web de Abivax, en la AMF y en el sistema EDGAR de la SEC.
Abivax es una empresa biotecnológica en etapa clínica que desarrolla tratamientos para enfermedades inflamatorias crónicas. Su principal candidato a fármaco, obefazimod (ABX464), se encuentra actualmente en ensayos clínicos de Fase 3 para el tratamiento de la colitis ulcerosa moderadamente a severamente activa.
Abivax (ABVX)는 2025년 3월 24일 프랑스 금융 시장 당국(AMF)에 보편적 등록 문서를 제출하고 미국 증권 거래 위원회(SEC)에 연례 보고서(20-F)를 제출했다고 발표했습니다.
보편적 등록 문서에는 2024년 연간 재무 보고서, 경영 보고서(기업 거버넌스 보고서 포함), 법정 감사인의 보고서가 포함되어 있습니다. 이러한 문서는 Abivax 웹사이트, AMF 및 SEC의 EDGAR 시스템에서 확인할 수 있습니다.
Abivax는 만성 염증 질환 치료제를 개발하는 임상 단계의 생명공학 회사입니다. 그들의 주요 약물 후보인 obefazimod (ABX464)는 현재 중등도에서 중증의 활동성 궤양성 대장염 치료를 위한 3상 임상 시험에 있습니다.
Abivax (ABVX) a annoncé le dépôt de son Document d'Enregistrement Universel auprès des Autorités des Marchés Financiers Françaises (AMF) et de son Rapport Annuel (20-F) auprès de la Commission des Valeurs Mobilières des États-Unis (SEC) le 24 mars 2025.
Le Document d'Enregistrement Universel comprend le rapport financier annuel 2024, le rapport de gestion incluant le rapport sur la gouvernance d'entreprise et les rapports des commissaires aux comptes. Ces documents seront accessibles sur le site web d'Abivax, auprès de l'AMF et dans le système EDGAR de la SEC.
Abivax est une entreprise biopharmaceutique en phase clinique qui développe des traitements pour les maladies inflammatoires chroniques. Leur principal candidat médicament, obefazimod (ABX464), est actuellement en essais cliniques de Phase 3 pour le traitement de la colite ulcéreuse modérément à sévèrement active.
Abivax (ABVX) hat die Einreichung seines Universellen Registrierungsdokuments bei den französischen Finanzmarktbehörden (AMF) und seinen Jahresbericht (20-F) bei der US-amerikanischen Securities and Exchange Commission (SEC) am 24. März 2025 bekannt gegeben.
Das Universelle Registrierungsdokument enthält den Jahresfinanzbericht 2024, den Managementbericht einschließlich des Berichts zur Unternehmensführung und die Berichte der gesetzlichen Prüfer. Diese Dokumente werden auf der Website von Abivax, bei der AMF und im EDGAR-System der SEC verfügbar sein.
Abivax ist ein biopharmazeutisches Unternehmen in der klinischen Phase, das Behandlungen für chronisch entzündliche Erkrankungen entwickelt. Ihr Hauptkandidatenmedikament, obefazimod (ABX464), befindet sich derzeit in Phase-3-Studien zur Behandlung von mäßig bis schwer aktiver Colitis ulcerosa.
- Lead drug candidate obefazimod advancing in Phase 3 trials for ulcerative colitis
- None.
Abivax publishes financial reports with the French and U.S. securities regulatory agencies
PARIS, France – March 26, 2025 – 10:05 PM CET – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, announces the filing of its Universal Registration Document (Document d’Enregistrement Universel) with the French Financial Market Authorities, Autorité des Marchés Financiers (AMF), and the filing of its Annual Report (20-F) with the U.S. Securities and Exchange Commission (SEC) on March 24, 2025.
The Universal Registration Document includes the 2024 annual financial report, the management report including the report on corporate governance, as well as the reports of the statutory auditors.
The documents will be available for download on the website of Abivax (www.abivax.com/investors), the AMF (www.amf-france.org), and the SEC (www.sec.gov/edgar).
About Abivax
Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.
Contact:
Patrick Malloy
SVP, Investor Relations
Abivax SA
patrick.malloy@abivax.com
+1 847 987 4878
FAQ
What regulatory filings did Abivax (ABVX) submit in March 2025?
What is the current development stage of Abivax's (ABVX) lead drug candidate obefazimod?
Where can investors access Abivax's (ABVX) 2024 annual financial report?
What therapeutic area does Abivax (ABVX) focus on?
